



PRESS RELEASE

Indoco revenues grow 9% for the Financial Year 2022-23

Mumbai, May 23, 2023: During the fourth quarter of FY 2022-23, revenues of Indoco Remedies grew by 6.9 % at Rs. 428.0 crores, as against Rs. 400.3 crores, same quarter last year. EBIDTA to net sales for the quarter is 15.0 % at Rs. 64.2 crores, compared to 20.1 % at Rs. 80.5 crores, same quarter last year. For the quarter, the Profit After Tax is at Rs. 25.4 crores, compared to Rs. 40.4 crores, same quarter last year. Profit After Tax with other comprehensive income is at Rs. 29.7 crores, compared to Rs.35.6 crores, same quarter last year.

For the year ended Mar'23, the revenues grew by 9.0 % at Rs. 1638.1 crores, as against Rs. 1502.7 crores, same period last year. EBIDTA to net sales for the period is 17.4 % at Rs. 284.9 crores, compared to 21.8 % at Rs. 327.0 crores, same period last year. For the period, the Profit After Tax is at Rs. 141.4 crores, compared to Rs. 154.5 crores, same period last year. Profit After Tax with other comprehensive income is at Rs. 142.8 crores, compared to Rs. 149.2 crores, same period last year.

Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, "Our performance this year is a function of a predictable performance of India business, free of COVID impact, accompanied by a good performance of Export business".

About Indoco Remedies Limited:

Indoco is a fully integrated, research-oriented pharmaceutical company with presence in 55 countries. The Company's turnover is US\$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff who are the strength of the organization.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynecology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Pramod Ghorpade

Mobile: 9619883225

E-mail: pramod.ghorpade@indoco.com / corpcom@indoco.com